HOME HELP FEEDBACK HOW TO CITE ABSTRACTS ARCHIVE CME INFORMATION SEARCH Cancer Research Clinical Cancer Research Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics Molecular Cancer Research Cancer Prevention Research Cancer Prevention Journals Portal Cancer Reviews Online Annual Meeting Education Book Meeting Abstracts Online		QUICK SEARCH:   [advanced] Author: Keyword(s):

This Article Services Similar articles in this journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Narita, K. Articles by Shridhar, V. Search for Related Content PubMed Articles by Narita, K. Articles by Shridhar, V.

Preclinical Studies and Early Drug Development: Other Preclinical Studies

Downregulation of HSulf-1 promotes autocrine signaling in breast cancer

Mayo Clinic and Foundation, Rochester, MN

Abstract

B39

Heparan sulfate glycosaminoglycans (HS-GAGs) are the oligosaccharide chains of heparan sulfate proteoglycans and interact with various extracellular signaling molecules as a low-affinity receptor to regulate their activities. The sulfation of HS-GAG residues is required for its interaction with heparin-binding growth factors to activate their high-affinity receptor tyrosine kinases. The alterations in HS-GAG sulfation and the consequences associated with pathology are, however, poorly characterized. The HS-GAG endosulfatase HSulf-1 is downregulated in ovarian, breast and several other cancer cell lines. Here we show that HSulf-1 inhibits autocrine activation of the EGFR-ERK pathway induced by serum withdrawal in MDA-MB-468 breast cancer cells. The neutralization antibodies against the heparin-binding growth factor family of the EGF superfamily, amphiregulin and HB-EGF, inhibit autocrine signaling. Furthermore, HSulf-1-mediated inhibition of autocrine signaling was associated with reduced cyclinD1 levels, leading to decreased S-phase fraction and increased G2-M fraction, and increased cell death. Finally, evaluation of HSulf-1 expression levels in primary invasive breast tumors by RNA in situ hybridization indicated that HSulf-1 is downregulated in majority (60%) of tumors. These data suggest a potential role of HSulf-1 in mammary carcinogenesis.